[{"id":"71b6e7a1-e8f9-4246-9907-95c8f1bd4257","acronym":"","url":"https://clinicaltrials.gov/study/NCT06162572","created_at":"2023-12-08T19:16:46.816Z","updated_at":"2025-02-25T14:42:34.136Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06162572","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • S95018 • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 08/07/2024","start_date":" 08/07/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-14"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"}]